Cadila Healthcare receives EIR for Baddi unit

31 Oct 2019 Evaluate

Cadila Healthcare has received an Establishment Inspection Report (EIR) for its formulations manufacturing facility located at Baddi, India. The US Food and Drug Administration (USFDA) had conducted an inspection at the facility from July 15, 2019 to July 19, 2019. The EIR report stated that the classification of the facility is ‘No Action Indicated (NAI)’.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×